GlassScriptPhysician profile
Cameron J Pappas
NPI 1104579986
$18,341.56
in general payments reported to CMS, 2019-2025
28 companies · $7,588 in 2025
The $7,588 reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $3,546 · 2024: $7,208 · 2025: $7,588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17K · Consulting Fee: $750 · Travel and Lodging: $398 · Education: $274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16,919.96 |
| Consulting Fee | $750.00 |
| Travel and Lodging | $397.52 |
| Education | $274.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,889.17 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $2,555.31 | 2023-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $2,553.21 | 2023-2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $1,527.46 | 2024-2025 | Zoryve |
| Incyte Corporation | $1,297.47 | 2023-2025 | Opzelura, Opzelura |
| Genzyme Corporation | $1,238.35 | 2023-2025 | |
| Revance Therapeutics, INC. | $989.78 | 2024-2025 | Daxxify |
| Lilly USA, LLC | $832.76 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Dermavant Sciences, INC. | $619.64 | 2023-2024 | Vtama |
| Ucb, INC. | $597.78 | 2023-2025 | Bimzelx, Cimzia |
| Amgen INC. | $546.69 | 2023-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $535.16 | 2023-2025 | Nemluvio, Aklief, Twyneo |
| Organogenesis INC. | $474.04 | 2025 | Simplimax, Affinity, Nushield |
| Sun Pharmaceutical Industries INC. | $449.02 | 2023-2025 | Winlevi, Absorica Ld, Ilumya |
| Pfizer INC. | $410.72 | 2023-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $175.84 | 2023-2025 | |
| Organon LLC | $160.63 | 2025 | Vtama |
| Verrica Pharmaceuticals INC. | $114.43 | 2024 | Ycanth |
| Takeda Pharmaceuticals U.S.A., INC. | $97.13 | 2025 | |
| Sanofi-Aventis U.S. LLC | $72.00 | 2023 | |
| Convatec INC. | $53.75 | 2024 | |
| Sanofi US Services INC. | $51.48 | 2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $22.79 | 2023 | Targretin, Duobrii, Siliq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.49 | 2025 | Spevigo |
| Aurinia Pharma U.S., INC. | $15.50 | 2023 | Lupkynis |
| Leo Pharma INC. | $14.78 | 2023 | Adbry |
| Botanix Sb INC | $14.01 | 2025 | Sofdra |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cameron Pappas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.